WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery system at Hollings Cancer Center. Here’s the story on this important medical advance for prostate cancer patients and the doctors who treat...
The world’s first use of the Blu Build Cesium-131 brachytherapy delivery system to treat prostate cancer at Hollings Cancer Center is an important development for prostate cancer patients and their doctors. Here’s the WTAT-TV...
Conference Call is February 12 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 30, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today...
RICHLAND, WASHINGTON – January 29, 2018 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Hollings Cancer Center at the Medical...
“I urge newly diagnosed men to see a range of specialists before selecting treatment. After talking to a urologist, they should make independent appointments with a radiation oncologist, a medical oncologist, and a brachytherapist to ensure that they become fully...
RICHLAND, WASHINGTON – December 17, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Lori Woods has been named Chief Executive...
As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types. He was kind enough to share his thoughts with us in a video...
RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...
Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer. This study aimed to evaluate the effects on survival rate in patients...
